2019 scientific publications show that vaccines delivered to the lungs are highly effective being more effective than traditional injection vaccines and provide broader cross-reactive and long-lasting protection. Bringing together key players in aerosol delivery, academic excellence in vaccines, industrial support and clinical research organisation expertise, Revax Biotech promises to deliver a revolution in vaccination.